This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
mCRPC in focus

Transcript: Barriers to uptake of clinical practice guidelines for mCRPC

Last updated:4th Sep 2024
Published:4th Sep 2024

Professor Axel Merseburger

All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.

So the question is, what are the clinical barriers to uptake of clinical practice guidelines for mCRPC? And it is really, really depending on the patient profile, and also on novel developments we have. And guidelines are only as fast as the guidelines panel will take those changes in the scientific world, and what we learn from publications from recent approvals into their recommendations.

So, sometimes an approval of another substance is much faster than the guidelines recommendations. So, this is something what we need to keep in mind, and that's why we need to inform ourself, and all, let's say, channels we can use like from the internet, from PubMed, from society recommendation, and surely the updates from the guidelines. And also, let me give you an example. The patients that undergo genetic testing which is recommended in those modern guidelines, it's not always so easy to do this because of rural areas, because of long travel distances, because of the pandemic situation we have had the last couple years. So, a lot of aspects that play an important role in our clinical decision-making, and why we might have barriers in those guidelines for treating men with mCRPC.

And hopefully in the future, modern developments, or approval of substances, and combinations deliver easier options for all patients.

View the video

Welcome: